These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 16979839)

  • 1. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.
    Hofheinz RD; Horisberger K; Woernle C; Wenz F; Kraus-Tiefenbacher U; Kähler G; Dinter D; Grobholz R; Heeger S; Post S; Hochhaus A; Willeke F
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1384-90. PubMed ID: 16979839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
    Horisberger K; Treschl A; Mai S; Barreto-Miranda M; Kienle P; Ströbel P; Erben P; Woernle C; Dinter D; Kähler G; Hochhaus A; Post S; Willeke F; Wenz F; Hofheinz RD;
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1487-93. PubMed ID: 19131187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.
    Kim SY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Lee KS; Yun T; Jeong SY; Choi HS; Lim SB; Chang HJ; Jung KH
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):677-83. PubMed ID: 20888703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer.
    Hofheinz RD; von Gerstenberg-Helldorf B; Wenz F; Gnad U; Kraus-Tiefenbacher U; Müldner A; Hehlmann R; Post S; Hochhaus A; Willeke F
    J Clin Oncol; 2005 Mar; 23(7):1350-7. PubMed ID: 15684318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.
    Malik I; Hussein F; Bush D; Alqaisi M; Bernal P; Byrd J; Garberoglio C
    Am J Clin Oncol; 2010 Jun; 33(3):242-5. PubMed ID: 19806036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
    Kim SY; Shim EK; Yeo HY; Baek JY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Jung KH; Chang HJ
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):201-7. PubMed ID: 22672749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.
    Willeke F; Horisberger K; Kraus-Tiefenbacher U; Wenz F; Leitner A; Hochhaus A; Grobholz R; Willer A; Kähler G; Post S; Hofheinz RD
    Br J Cancer; 2007 Mar; 96(6):912-7. PubMed ID: 17325705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer.
    Rödel C; Arnold D; Hipp M; Liersch T; Dellas K; Iesalnieks I; Hermann RM; Lordick F; Hinke A; Hohenberger W; Sauer R
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1081-6. PubMed ID: 17881150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients.
    Ugidos L; Delgado S; Conill C; Ginés A; Gallego R; Ayuso JR; Miquel R; Tosca M; de Lacy A; Castells A; Maurel J
    Invest New Drugs; 2009 Jun; 27(3):262-8. PubMed ID: 18923810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
    Erben P; Ströbel P; Horisberger K; Popa J; Bohn B; Hanfstein B; Kähler G; Kienle P; Post S; Wenz F; Hochhaus A; Hofheinz RD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1032-8. PubMed ID: 20947270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
    Chiorean EG; Sanghani S; Schiel MA; Yu M; Burns M; Tong Y; Hinkle DT; Coleman N; Robb B; LeBlanc J; Clark R; Bufill J; Curie C; Loehrer PJ; Cardenes H
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):25-32. PubMed ID: 22610353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
    Glynne-Jones R; Falk S; Maughan TS; Meadows HM; Sebag-Montefiore D
    Br J Cancer; 2007 Feb; 96(4):551-8. PubMed ID: 17262086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.
    Wong SJ; Winter K; Meropol NJ; Anne PR; Kachnic L; Rashid A; Watson JC; Mitchell E; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1367-75. PubMed ID: 21775070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine, irinotecan, oxaliplatin (CAPIRINOX) and concomitant irradiation in advanced rectal cancer: the Lyon R-02-01 phase I trial.
    Heudel P; Romestaing P; Barbet N; Falandry C; You B; Glehen O; Freyer G
    Clin Oncol (R Coll Radiol); 2008 Jun; 20(5):369-74. PubMed ID: 18406583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.
    Gollins S; Sun Myint A; Haylock B; Wise M; Saunders M; Neupane R; Essapen S; Samuel L; Dougal M; Lloyd A; Morris J; Topham C; Susnerwala S
    J Clin Oncol; 2011 Mar; 29(8):1042-9. PubMed ID: 21263095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer.
    Velenik V; Ocvirk J; Oblak I; Anderluh F
    Eur J Surg Oncol; 2010 Mar; 36(3):244-50. PubMed ID: 20042310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Dunst J; Reese T; Sutter T; Zühlke H; Hinke A; Kölling-Schlebusch K; Frings S
    J Clin Oncol; 2002 Oct; 20(19):3983-91. PubMed ID: 12351595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
    Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial.
    Eisterer W; De Vries A; Öfner D; Rabl H; Koplmüller R; Greil R; Tschmelitsch J; Schmid R; Kapp K; Lukas P; Sedlmayer F; Höfler G; Gnant M; Thaler J;
    Anticancer Res; 2014 Nov; 34(11):6767-73. PubMed ID: 25368289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
    Cartwright T; Kuefler P; Cohn A; Hyman W; Berger M; Richards D; Vukelja S; Nugent JE; Ruxer RL; Boehm KA; Asmar L
    Clin Colorectal Cancer; 2008 Nov; 7(6):390-7. PubMed ID: 19036692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.